The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors.
 
Alison M. Schram
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Kura Oncology (Inst); Lilly (Inst); Merus (Inst); Northern Biologics (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Surface Oncology (Inst)
 
Suneel Deepak Kamath
Consulting or Advisory Role - Exelixis; OncLive; Tempus
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Foundation Medicine; Guardant Health; Ipsen; Janssen; Merck
 
Anthony B. El-Khoueiry
Honoraria - ABL bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; Roche/Genentech
Consulting or Advisory Role - ABL Bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; Roche
Research Funding - Astex Pharmaceuticals; AstraZeneca; Merck
 
Mitesh J. Borad
Stock and Other Ownership Interests - AVEO; Gilead Sciences; Intercept Pharmaceuticals; Spectrum Pharmaceuticals
Consulting or Advisory Role - Agios (Inst); ArQule (Inst); Celgene (Inst); De Novo Pharmaceuticals; Exelixis; Fujifilm (Inst); G1 Therapeutics; Genentech; Halozyme (Inst); Immunovative Therapies; Imvax; Inspyr Therapeutics; Insys Therapeutics (Inst); Klus Pharma; Lynx Group; Merck; Novartis (Inst); Pieris Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Western Oncolytics
Research Funding - Adaptimmune (Inst); Agios (Inst); ARIAD (Inst); Basilea (Inst); BiolineRx (Inst); Boston Biomedical (Inst); Celgene (Inst); Dicerna (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); ImClone Systems (Inst); Incyte (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); MedImmune (Inst); Merck Serono (Inst); miRNA Therapeutics (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); RedHill Biopharma (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Sun Biopharma (Inst); Taiho Pharmaceutical (Inst); Threshold Pharmaceuticals (Inst); Toray Industries (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Celgene
 
Kabir Mody
Stock and Other Ownership Interests - CytoDyn; Oncotherapeutics
Consulting or Advisory Role - AstraZeneca; Celgene; Eisai; Genentech/Roche; Ipsen; Merrimack; Vicus Therapeutics
Research Funding - Agios; ARIAD; ArQule; AstraZeneca (Inst); Basilea (Inst); FibroGen; Gritstone Bio (Inst); Incyte (Inst); MedImmune; Merck (Inst); Senhwa Biosciences; Taiho Pharmaceutical; TRACON Pharma; Turnstone Bio (Inst); Vyriad (Inst)
 
Amit Mahipal
Honoraria - Eisai
Consulting or Advisory Role - QED Therapeutics
Research Funding - Taiho Pharmaceutical
 
Lipika Goyal
Consulting or Advisory Role - Agios; Alentis Therapeutics; AstraZeneca; Debiopharm Group; Exelixis; Genentech; H3 Biomedicine; Incyte; Klus Pharma; QED Therapeutics; Sirtex Medical; Taiho Pharmaceutical
(OPTIONAL) Uncompensated Relationships - Agios; Debiopharm Group; Merck; Taiho Pharmaceutical
 
Vaibhav Sahai
Consulting or Advisory Role - AstraZeneca; Celgene; Halozyme; Incyte; Ipsen; Klus Pharma; Newlink Genetics; QED Therapeutics
Research Funding - Agios (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); FibroGen (Inst); Halozyme (Inst); Incyte (Inst); Ipsen (Inst); MedImmune (Inst); Rafael Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - ASCO; FibroGen; FibroGen
 
Oleg Schmidt-Kittler
Employment - Blueprint Medicines; Relay Therapeutics
Stock and Other Ownership Interests - Blueprint Medicines; Relay Therapeutics
Patents, Royalties, Other Intellectual Property - Patent with Blueprint Medicines
Travel, Accommodations, Expenses - Blueprint Medicines; Relay Therapeutics
 
Jinshan Shen
Employment - Relay Therapeutics
Stock and Other Ownership Interests - Relay Therapeutics
 
Kai Yu Jen
Employment - Relay Therapeutics
Stock and Other Ownership Interests - Relay Therapeutics
 
Alicia Deary
Employment - Kiniksa; Relay Therapeutics
Stock and Other Ownership Interests - Alexion Pharmaceuticals; Yield Ten Bioscencies (I)
Travel, Accommodations, Expenses - Kiniksa
 
Cori Ann Sherwin
Employment - Blueprint Medicines; Relay Therapeutics
Stock and Other Ownership Interests - Alexion Pharmaceuticals; Blueprint Medicines; Relay Therapeutics
 
Mahesh Padval
Employment - Relay Therapeutics
Stock and Other Ownership Interests - Relay Therapeutics; Verastem
 
Beni B. Wolf
Employment - Relay Therapeutics
Stock and Other Ownership Interests - Relay Therapeutics
 
Vivek Subbiah
Consulting or Advisory Role - Helsinn Therapeutics; Loxo; MedImmune; QED Therapeutics; R-Pharm
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; Helsinn Therapeutics; Novartis; PharmaMar
Other Relationship - Medscape